Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel
NASDAQ:BMRA

Biomerica Q3 2025 Earnings Report

Biomerica logo
$2.51 +0.15 (+6.36%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$2.50 -0.01 (-0.40%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Biomerica EPS Results

Actual EPS
-$0.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biomerica Revenue Results

Actual Revenue
$1.12 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomerica Announcement Details

Quarter
Q3 2025
Date
4/14/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biomerica's next earnings date is estimated for Wednesday, October 21, 2026, based on past reporting schedules.

Conference Call Resources

Biomerica Earnings Headlines

Biomerica Posts Narrower Q4 Loss On Higher Sales; Stock Down
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687774/biomerica-posts-narrower-q4-loss-on-higher-sales-stock-down.aspx
Biomerica Reports Fiscal 2026 Fourth-Quarter Sales Growth, Improved Full-Year Loss and Advances in inFoods IBS Commercialization
September 1, 2026  |  quiverquant.comQ
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.tc pixel
September 20 at 1:00 AM  |  Paradigm Press (Ad)
Biomerica Reports Fiscal 2026 Year-End Financial Results
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354133/0/en/biomerica-reports-fiscal-2026-year-end-financial-results.html
Biomerica Inc.
August 31, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/bmra-biomerica-inc/vitals
Biomerica Announces $2.23 Million Private Placement at $1.60 per Share and Engages B. Riley to Review Strategic Alternatives
August 27, 2026  |  quiverquant.comQ
See More Biomerica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomerica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomerica and other key companies, straight to your email.

About Biomerica

Biomerica (NASDAQ:BMRA) is a medical technology company that develops, manufactures and commercializes diagnostic and therapeutic products, with a primary focus on gastrointestinal disorders and other medical conditions. The company is headquartered in Irvine, California, and serves healthcare providers and patients in the United States and selected international markets through direct sales and distribution relationships.

Biomerica’s principal product is inFoods IBS, a diagnostic-guided dietary management program for irritable bowel syndrome. The program combines a blood-based test intended to identify foods that may contribute to an individual’s symptoms with a personalized dietary plan designed to help patients manage those symptoms. Biomerica has also developed and marketed diagnostic products addressing gastrointestinal and infectious-disease applications.

The company has historically focused on combining diagnostic testing with individualized treatment or dietary-management approaches. Zackary Irani serves as Biomerica’s president and chief executive officer and has been associated with the company’s leadership for several years.

View Biomerica Profile
Earnings Tools